title: OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy.
abstract: OBJECTIVE
  To study the precise structural aspects of a type 2 neovascular membrane in a patient with age-related macular degeneration (AMD) using optical coherence tomography (OCT) angiography and perform sequential quantitative analysis of the membrane after ranibizumab therapy.
  
  
  METHODS
  Split-spectrum amplitude-decorrelation (SSADA) OCT angiography macular cubes (3 × 3 mm) were acquired with a light source centered at 840 nm, a bandwidth of 45 nm, and an A-scan-rate of 70 000 scans per second. Visible pathologic vessels were outlined manually on average intensity projection en face images, and the area of the lesion and the vessel density were measured at baseline and follow-up.
  
  
  RESULTS
  At baseline, the neovascular lesion measured 4.12 mm(2) and the vessel density was 19.83 mm(-1). Four weeks after the first, and 2 and 4 weeks after the second ranibizumab injection, OCT angiography revealed a progressively smaller vascular lesion (2.32, 1.77 and 1.64 mm(2)), and vessel density (10.24, 8.52 and 7.57 mm(-1)), although the large central trunks of the lesion were unchanged.
  
  
  CONCLUSIONS
  In this study, an obvious reduction in size and vessel density of the neovascular lesion was noted after treatment with ranibizumab using SSADA OCT angiography technology. Microvascular components can be delineated with precision, suggesting that this technique may be useful for the management of patients with neovascular AMD in a clinical setting as well as for future clinical trials.
authors.affiliation: 1] Doheny Eye Institute, Los Angeles, CA, USA [2] Stein Eye Institute, Los Angeles, CA, USA.
authors.forename: L
authors.initials: L
authors.lastname: Kuehlewein
authors.affiliation: 1] Doheny Eye Institute, Los Angeles, CA, USA [2] Stein Eye Institute, Los Angeles, CA, USA.
authors.forename: S R
authors.initials: SR
authors.lastname: Sadda
authors.affiliation: 1] Stein Eye Institute, Los Angeles, CA, USA [2] Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA [3] Greater Los Angeles VA Healthcare Center, Los Angeles, CA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Sarraf
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000627:therapeutic use*; D012166:Retinal Hemorrhage / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab